Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Immunomedics, Inc. Identifier:
First received: January 5, 2012
Last updated: February 12, 2015
Last verified: February 2015